Logo de la BVS

    • Español
    • English
    • Português
    • Français
    Inicio > > Semaglutide for managing overweight and obesity

    Semaglutide for managing overweight and obesity

    England. National Institute for Health and Care Excellence.
    Año de publicación: 2023

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults. Commercial availability The Wegovy brand of semaglutide is not commercially available yet.
    Insulin/therapeutic use, Obesity Management, Overweight/drug therapy, Exercise, Caloric Restriction
    Texto completo

    Relacionados

    • Términos y condiciones de uso
    • Política de Privacidad
    • WordPress version 4.9.8
    • BVS-Site Plugin version 0.6.0